Copyright
©The Author(s) 2022.
World J Crit Care Med. Jul 9, 2022; 11(4): 246-254
Published online Jul 9, 2022. doi: 10.5492/wjccm.v11.i4.246
Published online Jul 9, 2022. doi: 10.5492/wjccm.v11.i4.246
Table 1 Demographic and primary clinical characteristics in the Sepsis, vasoplegic shock and septic shock 3.0 groups
| IQR | Sepsis | Vasoplegic shock | Septic shock 3.0 | Total | P |
| (n = 51) | (n = 26) | (n = 41) | (n = 118) | ||
| Age, years (mean ± SD) | 59.51 ± 13.7 | 61.9 ± 12.9 | 68.7 ± 10.6 | 63.3 ± 13.1 | 0.005 |
| Gender, males (n) | 38 | 19 | 30 | 87 | 0.986 |
| Body mass index (mean ± SD) | 27.56 ± 4.44 | 29.67 ± 6.7 | 27.9 ± 4.1 | 28.2 ± 4.9 | 0.591 |
| SOFA at admission [mean (IQR)] | 3.04 (2; 4) | 5.88 (3; 8) | 7.14 (4; 9) | 5.13 (2; 7.8) | < 0.001 |
| Mechanical ventilation (n) | 5 | 26 | 37 | 68 | < 0.001 |
| Length of mechanical ventilation, d [mean (IQR)] | 1.06 (0; 2) | 12.5 (4.75;17) | 19.3 (7.5; 28) | 9.9 (0; 17.3) | < 0.001 |
| Minimum paO2/FiO2 registered (mean ± SD) | 181.9 ± 82.1 | 104.9 ± 69.2 | 92 ± 64.5 | 133.7 ± 84.4 | < 0.001 |
| Ventilation in prone position, h [mean (IQR)] | 4.55 (3; 5.1) | 70.2 (0; 134.8) | 129.1 (0; 187.5) | 62.3 (0; 96) | < 0.001 |
| Length of neuromuscular blockade, d [mean (IQR)] | 0 (0; 0) | 6.5 (2; 9.3) | 8.3 (3; 16.5) | 4.9 (0; 8.3) | < 0.001 |
| Vasopressor support (n) | 0 | 26 | 41 | 67 | < 0.001 |
| Minimum blood pressure registered, mmHg (mean ± SD) | 60.1 ± 11.3 | 52.8 ± 8.1 | 48.7 ± 9.5 | 54.5 ± 11.2 | < 0.001 |
| Maximum dose of vasopressor therapy, µg/kg (mean ± SD) | - | 22.5 ± 18.8 | 30.5 ± 16.3 | 15.6 ± 18.9 | < 0.001 |
| Maximum serum lactate level, mg/dL (mean ± SD) | 1.64 ± 0.56 | 1.39 ± 0.35 | 3.88 ± 2.8 | 2.36 ± 2 | < 0.001 |
| Maximum serum troponin level, ng/mL [mean (IQR)] | 22.04 (6; 25) | 103.4 (17.75; 124.8) | 129.7 (40; 166.5) | 77.4 (13; 93) | < 0.001 |
| Minimum serum hemoglobin level, g/dL (mean ± SD) | 11.4 ± 2.1 | 9.3 ± 2 | 8.1 ± 1.8 | 9.8 ± 2.5 | < 0.001 |
| Maximum serum C-reactive protein, mg/dL (mean ± SD) | 18.2 ± 9.45 | 30.2 ± 9.9 | 31.9 ± 8.8 | 25.6 ± 11.3 | < 0.001 |
| Maximum serum Procalcitonin, ng/mL [mean (IQR)] | 2.29 (0.1; 0.8) | 6.65 (0.4; 5.9) | 10.4 (1.1; 12.4) | 6.23 (0.3; 5.9) | < 0.001 |
| Maximum creatinine level registered, mg/dL [mean (IQR)] | 1.68 (0.82; 1.2) | 2.66 (0.83; 2.54) | 3 (1.3; 3.8) | 2.36 (0.9; 2.8) | < 0.001 |
| Renal support therapy (n) | 4 (8%) | 7 (3%) | 20 (49%) | 31 (26%) | < 0.001 |
| Secondary infections, per patient [mean (IQR)] | 0.16 (0; 0) | 0.63 (0; 1) | 1.1 (0; 1.5) | 0.55 (0; 1) | < 0.001 |
| Remdesivir (n, %) | 22 (43%) | 13 (50%) | 20 (49%) | 55 (47%) | 0.8 |
| Corticosteroid therapy (n) | 14 (27%) | 4 (15%) | 20 (49%) | 38 (32%) | 0.01 |
- Citation: Cidade JP, Coelho L, Costa V, Morais R, Moniz P, Morais L, Fidalgo P, Tralhão A, Paulino C, Nora D, Valério B, Mendes V, Tapadinhas C, Povoa P. Septic shock 3.0 criteria application in severe COVID-19 patients: An unattended sepsis population with high mortality risk. World J Crit Care Med 2022; 11(4): 246-254
- URL: https://www.wjgnet.com/2220-3141/full/v11/i4/246.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v11.i4.246